ClinicalTrials.gg
WithdrawnNCT02127697Updated Apr 13, 2015

Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma

A Phase 3 interventional study of NVA237 and Placebo to NVA237 in Asthma, sponsored by Novartis Pharmaceuticals. Withdrawn. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-04-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing glycopyrrolate in Asthma — 1 open to participants now, 1 under way, none of them phase 3. Glycopyrrolate · Asthma.

Enrollment
10th of 10
0 · median 69
Started
2015
with 1 other
Phase 3
3 of 10
none open now
Registered
1st of 10
by date
Lead sponsor
3 of 10
Novartis Pharmaceuticals

Among the 10 studies testing glycopyrrolate in Asthma, this one is the 10th largest by enrollment, is one of 2 that started in 2015, is one of 3 in phase 3, and was the 1st registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 10 studies testing glycopyrrolate in Asthma is open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing glycopyrrolate in Asthma, or all of them as a file.
02

Study summary

The study will assess efficacy, safety and tolerability of NVA237 compared to placebo in patients with poorly controlled asthma over 52 weeks of treatment.

Read the detailed description

The study will assess efficacy and safety of NVA237 compared to placebo, in addition to background therapy with LABA/ICS in patients with poorly controlled asthma.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma, poorly controlled asthma, LAMA, Long-Acting Muscarinic Antagonist, Glycopyrronium, Glycopyrronium bromide, Anticholinergic
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Written must be obtained before any assessment is performed; Male and female adult patients aged 18 to \<75 years; Patients with a diagnosis of asthma (according to GINA 2012) for a period of at least 5 years prior screening; The diagnosis of asthma must have been made before the patient was 40; Increase in (FEV1) of ≥ 12% and ≥ 200 mLs within 30 minutes after administration of 400 µg salbutamol/360 µg albuterol (or equivalent dose); Pre-bronchodilator FEV1 of ≥ 50 and ≤ 80% of the predicted normal value for the patient; Patients who qualify for treatment (according to GINA 2012) and have been treated with a stable dose of a fixed dose inhaled corticosteriod (ICS) and long-acting β2 agonist (LABA) combination for at least 4 weeks prior to screening. Patient must be using a total daily dose of ICS of ≥800 μg/day of budesonide of equivalent; All patients must be symptomatic with a mean ACQ-5 score ≥ 1.5 at Visit 101 and Visit 102; A documented history of one or more asthma exacerbations in the previous 12 months that required either treatment with additional or increased dose of systemic for at least 3 days, or an emergency room visit, or hospital treatment, or intubation

Exclusion criteria

Exclusion Criteria:

for treatment with, or having a history of reactions/ to any of the following inhaled drugs, drugs of a similar class, or any component thereof:

Muscarinic antagonist agents, sympathomimetic amines, lactose or any of the other of the study drug, long and short acting beta-2 agonists, ; Women of ; Resting ≥ 450 ms (male) or ≥ 460 ms (female) at Visit 101 (assessed by central reader) and at Visit 102 (assessed by investigator at the site); Patients with a (BMI) of more than 40 kg/m2; Patients who have renal, cardiovascular (such as but not limited to unstable ischemic heart disease, Class III/IV left ventricular failure, myocardial infarction, arrhythmia, neurological, endocrine, immunological, psychiatric, gastrointestinal, hepatic, or hematological abnormalities which could interfere with the assessment of the efficacy and safety of the study treatment; Patients with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia or bladder-neck obstruction or moderate to severe renal impairment or urinary retention (BPH patients who are stable on treatment can be considered); Patients who have had an asthma exacerbation that required either treatment with additional or increased dose of systemic corticosteroids for at least 3 days, or an emergency room visit, or hospital treatment, or intubation in the 6 weeks prior to screening; Patients who have smoked or inhaled tobacco products within the 6 month period prior to screening, or who have a smoking history of greater than 10 pack years (Note:10 pack years = 1 pack /day x 10 yrs., or ½ pack/day x 20 yrs.); Patients with a history of chronic lung diseases other than asthma, including (but not limited to) , bronchiectasis, sarcoidosis, interstitial lung disease, cystic fibrosis, and tuberculosis (unless tuberculosis is confirmed as no longer active by imaging); Patients on Maintenance Immunotherapy (desensitization) for allergies must have been so for at least 3 months prior to run-in, and must be expected to remain unchanged throughout the course of the study;

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    NVA237

    Participants will receive NVA237 once daily in addition to their background therapy during the 52- week treatment period. All participants will receive salbutamol/ albuterol as rescue medication.

    Drug: NVA237 · Drug: salbutamol/ albuterol

  • Placebo comparator
    Placebo

    Participants will receive placebo to NVA237 in addition to their background therapy during the 52-week treatment period. All participants will receive salbutamol/ albuterol as rescue medication.

    Drug: Placebo to NVA237 · Drug: salbutamol/ albuterol

Interventions

  • DrugNVA237

    NVA237 capsules for inhalation, delivered via Concept1 once daily

  • DrugPlacebo to NVA237

    Placebo to NVA237 delivered via Concept1 once daily

  • Drugsalbutamol/ albuterol

    Drug page: Albuterol

    Taken as rescue medication

06

What researchers measure

Primary outcomes

  1. Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 26

    Spirometry testing will be performed in accordance with American Thoracic Society standards. Trough FEV1 defined as the mean of two measurements at 23 hours 15 minutes and 23 hour 45 minutes post dosing.

    Time frame: Week 26

Secondary outcomes

  1. Time to First Moderate or Severe Asthma Exacerbation Over 52 Weeks of Treatment

    Asthma exacerbations are considered to be moderate if treatment with rescue systemic corticosteroids for greater than or equal to 3 days as outpatient or less than or equal to 24 hour emergency room visit was required. Asthma exacerbations are considered severe if treatment with rescue systemic corticosteroids for greater than or equal to 3 days and hospitalization or emergency department visit greater than 24 hours were required or death due to asthma. The time to the first moderate or severe asthma exacerbation is the study day on which the patient experienced first moderate or severe asthma exacerbation.

    Time frame: 52 weeks

  2. Asthma Control Questionnaire (ACQ-7) Overall Score at Week 26

    Asthma symptoms will be evaluated by the Asthma Control Questionnaire (ACQ-7). The ACQ has six questions to be answered by the patient, each with a 7 point scale (0-good control, 6-poor control), and one item where the actual pre-bronchodilator FEV1 value expressed in % of predicted FEV1. The overall score is an average of the 7 items.

    Time frame: Week 26

  3. Quality of Life as Assessed by Standardised Asthma Quality of Life Questionnaire (AQLQ(S)) Over 52-Week Treatment Period.

    There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental exposure). Each question will be answered on a 7 point scale (1-totally limited/problems all the time, 7-not at all limited/no problems). The overall AQLQ score is the mean of all 32 responses, and the individual domain scores are the means of the items in those domains (a minimum domain / overall score of 1 = Severely impaired whereas a maximum domain / overall score of 7 = not impaired at all). A positive change from baseline score indicates improvement.

    Time frame: Week 12, Week 26, Week 52

  4. Quality of Life Assessment With St. George's Respiratory Questionnaire (SGRQ) Over 52-Week Treatment Period

    SGRQ is a health related quality of life questionnaire consisting of 50 items in three components: symptoms, activity, and impacts. The lowest possible value is zero and the highest 100. Higher values correspond to greater impairment in quality of life.

    Time frame: Week 12, Week 26, Week 52

  5. Shortened Version of the Asthma Control Questionnaire (ACQ-6)

    This shortened version of the asthma control questionnaire (symptoms plus β2-agonist) consists of 6 items (nighttime waking, symptoms on waking, activity limitation, shortness of breath, wheeze and rescue short-acting β2-agonist use) between 0 and 6 (0 = maximum control; 6 = no control ) and a total score is the mean of 6 items.

    Time frame: Week 4, Week 8, Week 12, Week 26, Week 39, Week 52

  6. Shortened Version of the Asthma Control Questionnaire (ACQ-5)

    This shortened version of the asthma control questionnaire (symptoms only) consists of 5 items (nighttime waking, symptoms on waking, activity limitation, shortness of breath, and wheeze) between 0 and 6 (0 = maximum control; 6 = no control) and a total score is the mean of 5 items.

    Time frame: Week 4, Week 8, Week 12, Week 26, Week 39, Week 52

  7. Peak Forced Expiratory Volume in 1 Second (FEV1) Over 52 Weeks of Treatment

    Spirometry will be conducted according to internationally accepted standards. Peak FEV1= the maximum FEV1 recorded in the period between 0 minutes and 3 hours post dose.

    Time frame: Day 1, Week 4, Week 26, Week 52

  8. Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC0-3h) Over 52 Weeks of Treatment

    FEV1 will be measured with spirometry conducted according to internationally accepted standards. Measurements will be made at 5, 15, and 30 minutes; and 1, 2, and 3 hours post-dose.

    Time frame: Day 1, Week 4, Week 26, Week 52

  9. Predose Forced Expiratory Volume in 1 Second (FEV1) Over 52 Weeks of Treatment

    FEV1 will be measured with spirometry conducted according to internationally accepted standards. Predose FEV1 defined as the mean of FEV1 at -45 minutes and -15 minutes before the morning dose.

    Time frame: Week 2, Week 4, Week 8, Week 26, Week 39, Week 52

  10. Trough Forced Expiratory Volume in 1 Second (FEV1) Over 52 Weeks of Treatment

    FEV1 will be measured with spirometry conducted according to internationally accepted standards. Trough FEV1 defined as the mean of FEV1 23 hours 15 minutes and the 23 hours 45 minutes post dose.

    Time frame: Day 2, Week 4, Week 26, Week 52

  11. Mean Daily Number of Puffs of Rescue Medication Over 52 Weeks of Treatment

    Participants will maintain a diary to record the number of puffs of rescue Short-acting B2 agonist (SABA) used in the previous 24 hours to treat asthma symptoms.

    Time frame: 52 Weeks

  12. Rate of Moderate or Severe Asthma Exacerbation

    Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years

    Time frame: 52 Weeks

  13. Rate of Severe Asthma Exacerbation

    Rate of severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years

    Time frame: 52 Weeks

  14. Time To First Severe Asthma Exacerbation

    Asthma exacerbations are considered to be severe if treatment with rescue systemic corticosteroids for greater than or equal to 3 days and hospitalization or emergency department visit greater than 24 hours required or death due to asthma. The time to the first severe asthma exacerbation = the study day on which the patient experienced first severe asthma exacerbation.

    Time frame: 52 Weeks

  15. Time To First Asthma Exacerbation (Mild, Moderate, or Severe)

    Asthma exacerbation are considered Mild if treatment with inhaled or nebulized Short-acting B2 agonist (SABA), increase in inhaled corticosteroid only, or requires less than 3 days of systemic corticosteroids. Asthma exacerbations are considered to be moderate if treatment with rescue systemic corticosteroids for greater than or equal to 3 days as outpatient or less than or equal to 24 hour emergency room visit required. Asthma exacerbations are considered severe if treatment with rescue systemic corticosteroids for greater than or equal to 3 days and hospitalization or emergency department visit greater than 24 hours required or death due to asthma. The time to the first mild, moderate, or severe asthma exacerbation = the study day on which the patient experienced first asthma exacerbation of any severity.

    Time frame: 52 Weeks

  16. Rate of Asthma Exacerbation (Mild, Moderate, or Severe)

    Rate of mild, moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years

    Time frame: 52 Weeks

  17. Morning Daily Peak Expiratory Flow (PEF) Over 52 Weeks of Treatment

    Peak Expiratory Flow (PEF) will be measured every morning within 15 minutes of waking and before dosing using a peak flow meter, and recorded in the patient diary.

    Time frame: Every 3 Months, 52 Weeks

  18. Evening Daily Peak Expiratory Flow (PEF) Over 52 Weeks of Treatment

    Peak Expiratory Flow (PEF) will be measured every evening using a peak flow meter, and recorded in the patient diary.

    Time frame: Every 3 Months, 52 Weeks

  19. Asthma Control Diary (ACD) Symptom Score Over 52-Week Treatment Period

    The mean symptom score for ACD is defined as the sum of daily symptom scores divided by number of days where diary records were made. The daily symptom score for ACD is defined as the mean of the responses to the 5 symptom questions for any day with ACD questions answered.

    Time frame: Every 3 Months, 52 Weeks

  20. Lung Function Assessed by Forced Expiratory Volume for 1 Second (FEV1)

    FEV1 will be measured with spirometry conducted according to internationally accepted standards.

    Time frame: Week 1, Week 2, Week 4, Week 8, Week 12, Week 26, Week 39, Week 52

  21. Forced Vital Capacity (FVC)

    Forced Vital Capacity (FVC) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC will be assessed via spirometry. A positive change from baseline in FVC indicates improvement in lung function.

    Time frame: Week 2, Week 4, Week 8, Week 12, Week 26, Week 39, Week 52

  22. Asthma Control Questionnaire (ACQ-7) Over 52 Weeks of Treatment

    Asthma symptoms will be evaluated by the Asthma Control Questionnaire (ACQ). The ACQ has six questions to be answered by the patient, each with a 7 point scale (0-good control, 6-poor control), and one item where the actual pre-bronchodilator FEV1 value expressed in % of predicted FEV1. The overall score is an average of the 7 items.

    Time frame: Week 4, Week 8, Week 12, Week 26, Week 39, Week 52

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2015, a primary completion of May 2017 and a completion of May 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2014
First posted
May 1, 2014
Start
Mar 2015
Primary completionEst.
May 2017
CompletionEst.
May 2017
Last update
Apr 13, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02127697
Responsible party
Sponsor
First posted
May 1, 2014
Start date
Mar 2015
Primary completion
May 2017 (estimated)
Completion
May 2017 (estimated)
Last update
Apr 13, 2015

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion